Edition:
India

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.90USD
1:59am IST
Change (% chg)

$0.04 (+2.15%)
Prev Close
$1.86
Open
$1.87
Day's High
$1.90
Day's Low
$1.84
Volume
7,887
Avg. Vol
23,673
52-wk High
$4.50
52-wk Low
$1.35

Select another date:

Fri, Jan 12 2018

BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15

* JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING Source text: (http://bit.ly/2mkVVHQ) Further company coverage:

BRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To Seven

* SOLENO THERAPEUTICS SAYS ON JAN 2, BOARD RESOLVED TO DECREASE SIZE OF BOARD FROM TEN DIRECTORS TO SEVEN DIRECTORS - SEC FILING Source text for Eikon: (http://bit.ly/2F27EUa) Further company coverage:

BRIEF-Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics

* BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING Source text for Eikon: (http://bit.ly/2DT2Zn3) Further company coverage:

BRIEF-Soleno Therapeutics Announces $15 Million Private Placement

* SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT

BRIEF-Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology

* SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY

BRIEF-Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations

* Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results

BRIEF-Soleno Therapeutics regains compliance with Nasdaq listing requirements

* Soleno Therapeutics regains compliance with nasdaq listing requirements Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics announces 1-for-5 reverse stock split

* Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017 Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics receives scientific advice from EMA

* Soleno Therapeutics says ‍has received scientific advice from CHMP of European Medicines Agency regarding diazoxide choline controlled-release for treatment of prader-willi syndrome

BRIEF-Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

* Soleno Therapeutics presents updated safety and efficacy data from clinical trial of DCCR for treatment of Prader-Willi syndrome

Select another date: